Clinical research study| Volume 127, ISSUE 12, P1233-1241, December 2014

Acute Porphyrias in the USA: Features of 108 Subjects from Porphyrias Consortium



      Recent descriptions of the clinical and laboratory features of subjects with acute porphyrias in the US are lacking. Our aim was to describe clinical, biochemical, and genetic features of 108 subjects.


      Between September 2010 and December 2012, 108 subjects with acute porphyrias (90 acute intermittent porphyrias, 9 hereditary coproporphyrias, 9 variegate porphyrias) were enrolled into an observational study. Genetic testing was performed at a central genetic testing laboratory and clinical information entered into a central database. Selected features were compared with data for adults in the US.


      Most subjects (88/108, 81%) were female, with self-reported onset of symptoms in the second through fourth decades of life. The most common symptom was abdominal pain. Appendectomies and cholecystectomies were common before a diagnosis of porphyria. The diagnosis was delayed by a mean of 15 years. Anxiety and depression were common, and 18% complained of chronic symptoms, especially neuropathic and other pains. The incidences of systemic arterial hypertension, chronic kidney disease, seizure disorders, and psychiatric conditions were markedly increased. Mutations of the known causative genes were found in 102/105 of those tested, with novel mutations being found in 37, including in 7/8 subjects with hereditary coproporphyria. Therapy with intravenous hematin was the most effective therapy both for treatment of acute attacks and for prevention of recurrent attacks.


      Acute porphyrias often remain undiagnosed for more than a decade after first symptoms develop. Intravenous hematin is the treatment of choice, both for treatment of acute attacks and for prevention of recurrent attacks.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Balwani M.
        • Desnick R.J.
        The porphyrias: advances in diagnosis and treatment.
        Blood. 2012; 120: 4496-4504
        • Bonkovsky H.L.
        • Guo J.T.
        • Hou W.
        • Li T.
        • Narang T.
        • Thapar M.
        Porphyrin and heme metabolism and the porphyrias.
        Compr Physiol. 2013; 3: 365-401
        • Larion S.
        • Caballes F.R.
        • Hwang S.I.
        • Bonkovsky H.L.
        Circadian rhythms in acute intermittent porphyria a pilot study.
        Eur J Clin Invest. 2013; 43: 727-739
        • Bonkovsky H.L.
        Porphyrin and heme metabolism and the porphyrias.
        in: Zakim D. Boyer T.D. Hepatology–A Textbook of Liver Disease. 2nd ed. Elsevier, Philadelphia1990: 378-424
        • Anderson K.E.
        • Sassa S.
        • Bishop D.F.
        • Desnick R.J.
        Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias.
        in: Scriver C.R. Beaudet A.L. Sly W.S. Valle D. The Metabolic Basis of Inherited Disease. 8th ed. McGraw-Hill, New York2001: 2991-3062
        • Akagi R.K.N.
        • Inoue R.
        • Anderson K.E.
        • et al.
        delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations.
        Mol Genet Metab. 2006; 97: 329-336
        • Jeans J.B.
        • Savik K.
        • Gross C.R.
        • et al.
        Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series.
        Am J Med Genet. 1996; 65: 269-273
        • Stein J.A.
        • Tschudy D.P.
        Acute intermittent porphyria. A clinical and biochemical study of 46 patients.
        Medicine. 1970; 49: 1-16
        • Meissner P.N.
        • Corrigall A.V.
        • Hift R.J.
        Fifty years of porphyria at the University of Cape Town.
        S Afr Med J. 2012; 102: 422-426
        • Hift R.J.
        • Meissner P.N.
        An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity.
        Medicine. 2005; 84: 48-60
        • Mustajoki P.
        Variegate porphyria. Twelve years' experience in Finland.
        Q J Med. 1980; 49: 191-203
        • Whatley S.D.
        • Puy H.
        • Morgan R.R.
        • et al.
        Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation.
        Am J Hum Genet. 1999; 65: 984-994
        • Thunell S.
        • Floderus Y.
        • Henrichson A.
        • Harper P.
        Porphyria in Sweden.
        Physiol Res. 2006; 555: S109-S118
        • Poh-Fitzpatrick M.B.
        A plasma porphyrin fluorescence marker for variegate porphyria.
        Arch Dermatol. 1980; 116: 543-547
        • Anderson K.E.
        • Bloomer J.R.
        • Bonkovsky H.L.
        • et al.
        Recommendations for the diagnosis and treatment of the acute porphyrias.
        Ann Intern Med. 2005; 142: 439-450
        • Whatley S.D.
        • Mason N.G.
        • Woolf J.R.
        • Newcombe R.G.
        • Elder G.H.
        • Badminton M.N.
        Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene.
        Clin Chem. 2009; 55: 1406-1414
        • Elder G.
        • Harper P.
        • Badminton M.
        • Sandberg S.
        • Deybach J.C.
        The incidence of inherited porphyrias in Europe.
        J Inherit Metab Dis. 2012; 26: 476-483
        • Anderson K.E.
        • Collins S.
        Open-label study of hemin for acute porphyria: clinical practice implications.
        Am J Med. 2006; 119 (e19-801.e24): 801
        • Dowman J.K.
        • Gunson B.K.
        • Mirza D.F.
        • et al.
        Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis.
        Liver Transpl. 2012; 18: 195-200
        • Wahlin S.
        • Harper P.
        • Sardh E.
        • Andersson C.
        • Andersson D.E.
        • Ericzon B.G.
        Combined liver and kidney transplantation in acute intermittent porphyria.
        Transpl Int. 2010; 23: e18-e21
        • Badminton M.N.
        • Deybach J.C.
        Treatment of an acute attack of porphyria during pregnancy.
        Eur J Neurol. 2006; 13: 668-669